 Judith Hsia
Concepts (290)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 11 | 2024 | 475 | 2.370 |
Why?
| | Rivaroxaban | 10 | 2024 | 255 | 2.300 |
Why?
| | Coronary Disease | 21 | 2013 | 385 | 1.920 |
Why?
| | Estrogens, Conjugated (USP) | 12 | 2013 | 49 | 1.430 |
Why?
| | Factor Xa Inhibitors | 6 | 2024 | 172 | 1.430 |
Why?
| | Estrogen Replacement Therapy | 15 | 2012 | 146 | 1.340 |
Why?
| | Cholesterol, LDL | 11 | 2024 | 365 | 1.210 |
Why?
| | Postmenopause | 28 | 2013 | 366 | 1.110 |
Why?
| | Thrombosis | 7 | 2024 | 371 | 1.010 |
Why?
| | Myocardial Infarction | 12 | 2025 | 1046 | 0.950 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2024 | 445 | 0.910 |
Why?
| | Venous Thromboembolism | 7 | 2025 | 316 | 0.850 |
Why?
| | Aspirin | 9 | 2024 | 387 | 0.840 |
Why?
| | Fluorobenzenes | 4 | 2011 | 16 | 0.830 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2023 | 54 | 0.810 |
Why?
| | Women's Health | 7 | 2008 | 372 | 0.780 |
Why?
| | Stroke | 11 | 2021 | 1120 | 0.740 |
Why?
| | Medroxyprogesterone Acetate | 6 | 2013 | 36 | 0.730 |
Why?
| | Randomized Controlled Trials as Topic | 8 | 2025 | 1477 | 0.730 |
Why?
| | Lower Extremity | 7 | 2024 | 427 | 0.730 |
Why?
| | Heart Failure | 6 | 2025 | 2236 | 0.720 |
Why?
| | Coronary Artery Disease | 11 | 2024 | 698 | 0.670 |
Why?
| | Renal Insufficiency | 2 | 2021 | 162 | 0.670 |
Why?
| | Aged | 60 | 2025 | 23961 | 0.660 |
Why?
| | Pyrimidines | 4 | 2011 | 470 | 0.640 |
Why?
| | Platelet Aggregation Inhibitors | 7 | 2024 | 463 | 0.640 |
Why?
| | Vascular Surgical Procedures | 2 | 2024 | 303 | 0.630 |
Why?
| | Sulfonamides | 4 | 2011 | 513 | 0.630 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 617 | 0.610 |
Why?
| | Middle Aged | 61 | 2025 | 33479 | 0.580 |
Why?
| | Endovascular Procedures | 1 | 2022 | 312 | 0.560 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2025 | 2531 | 0.550 |
Why?
| | Estrogens | 5 | 2013 | 367 | 0.540 |
Why?
| | Hospitalization | 8 | 2025 | 2199 | 0.520 |
Why?
| | Calcinosis | 5 | 2010 | 235 | 0.520 |
Why?
| | Treatment Outcome | 20 | 2025 | 10811 | 0.490 |
Why?
| | Hysterectomy | 7 | 2008 | 129 | 0.480 |
Why?
| | Hormone Replacement Therapy | 5 | 2013 | 100 | 0.480 |
Why?
| | Calcium Carbonate | 4 | 2010 | 14 | 0.480 |
Why?
| | Female | 70 | 2025 | 73304 | 0.480 |
Why?
| | Hemorrhage | 6 | 2023 | 722 | 0.440 |
Why?
| | Coronary Angiography | 9 | 2024 | 317 | 0.420 |
Why?
| | Humans | 81 | 2025 | 137585 | 0.410 |
Why?
| | Metabolic Syndrome | 2 | 2009 | 354 | 0.390 |
Why?
| | Fibrin Fibrinogen Degradation Products | 4 | 2023 | 82 | 0.370 |
Why?
| | Heptanoic Acids | 2 | 2009 | 66 | 0.360 |
Why?
| | Arteries | 2 | 2022 | 269 | 0.350 |
Why?
| | Cardiovascular Diseases | 10 | 2024 | 2111 | 0.350 |
Why?
| | Outpatients | 3 | 2024 | 396 | 0.340 |
Why?
| | Risk Factors | 26 | 2025 | 10388 | 0.340 |
Why?
| | Male | 34 | 2025 | 67762 | 0.340 |
Why?
| | Dyslipidemias | 2 | 2010 | 176 | 0.340 |
Why?
| | Pyrroles | 2 | 2009 | 213 | 0.340 |
Why?
| | Lipoproteins | 2 | 2008 | 168 | 0.320 |
Why?
| | Biomarkers | 13 | 2025 | 4149 | 0.320 |
Why?
| | Follow-Up Studies | 23 | 2021 | 5131 | 0.310 |
Why?
| | Cholesterol, HDL | 6 | 2021 | 203 | 0.310 |
Why?
| | Integrin beta3 | 1 | 2008 | 11 | 0.300 |
Why?
| | Vitamin D | 3 | 2007 | 397 | 0.300 |
Why?
| | Lipoproteins, LDL | 1 | 2009 | 116 | 0.300 |
Why?
| | Arterial Occlusive Diseases | 2 | 2006 | 83 | 0.300 |
Why?
| | Double-Blind Method | 13 | 2024 | 1993 | 0.290 |
Why?
| | Cholesterol | 5 | 2009 | 410 | 0.280 |
Why?
| | Anticoagulants | 5 | 2025 | 664 | 0.280 |
Why?
| | Myocardial Revascularization | 3 | 2007 | 73 | 0.270 |
Why?
| | Death, Sudden, Cardiac | 1 | 2009 | 185 | 0.270 |
Why?
| | International Classification of Diseases | 2 | 2025 | 135 | 0.270 |
Why?
| | Proportional Hazards Models | 14 | 2010 | 1266 | 0.250 |
Why?
| | Heart Rate | 3 | 2009 | 822 | 0.250 |
Why?
| | Heparin | 3 | 2023 | 261 | 0.250 |
Why?
| | Triglycerides | 6 | 2009 | 524 | 0.250 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 96 | 0.250 |
Why?
| | Carotid Artery Diseases | 1 | 2006 | 64 | 0.250 |
Why?
| | Venous Thrombosis | 2 | 2025 | 190 | 0.240 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2006 | 140 | 0.230 |
Why?
| | Incidence | 11 | 2025 | 2804 | 0.230 |
Why?
| | Pulmonary Embolism | 3 | 2025 | 226 | 0.230 |
Why?
| | Lipase | 2 | 2021 | 69 | 0.220 |
Why?
| | C-Reactive Protein | 6 | 2010 | 410 | 0.220 |
Why?
| | Angina Pectoris | 1 | 2004 | 65 | 0.210 |
Why?
| | Rosuvastatin Calcium | 4 | 2011 | 22 | 0.210 |
Why?
| | Ventricular Function, Left | 3 | 2024 | 534 | 0.200 |
Why?
| | Peripheral Vascular Diseases | 1 | 2004 | 103 | 0.200 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 4 | 2009 | 201 | 0.200 |
Why?
| | Computed Tomography Angiography | 1 | 2024 | 129 | 0.200 |
Why?
| | Patient Selection | 1 | 2007 | 696 | 0.200 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 51 | 0.200 |
Why?
| | Stroke Volume | 2 | 2024 | 612 | 0.200 |
Why?
| | Brain Ischemia | 2 | 2021 | 338 | 0.200 |
Why?
| | Walking | 2 | 2022 | 529 | 0.200 |
Why?
| | Risk | 8 | 2013 | 912 | 0.190 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2025 | 261 | 0.190 |
Why?
| | Lipoproteins, HDL | 2 | 2021 | 77 | 0.190 |
Why?
| | Indoles | 5 | 2009 | 412 | 0.190 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2021 | 34 | 0.180 |
Why?
| | Diet, Fat-Restricted | 3 | 2006 | 79 | 0.180 |
Why?
| | Hyperglycemia | 1 | 2025 | 347 | 0.180 |
Why?
| | Ischemia | 2 | 2021 | 409 | 0.180 |
Why?
| | Hypertension | 3 | 2025 | 1295 | 0.180 |
Why?
| | Risk Assessment | 8 | 2025 | 3457 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 173 | 0.180 |
Why?
| | Myocardial Ischemia | 3 | 2010 | 263 | 0.180 |
Why?
| | Enoxaparin | 1 | 2021 | 63 | 0.180 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 270 | 0.170 |
Why?
| | Proprotein Convertase 9 | 1 | 2021 | 73 | 0.170 |
Why?
| | Inflammation | 3 | 2023 | 2837 | 0.170 |
Why?
| | Hospital Mortality | 2 | 2021 | 911 | 0.160 |
Why?
| | Motor Activity | 1 | 2005 | 718 | 0.160 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1040 | 0.160 |
Why?
| | Drug Therapy, Combination | 5 | 2024 | 1066 | 0.160 |
Why?
| | Mobile Applications | 1 | 2022 | 183 | 0.160 |
Why?
| | Blood Glucose | 3 | 2025 | 2186 | 0.150 |
Why?
| | Patient Care Team | 1 | 2024 | 631 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 353 | 0.150 |
Why?
| | United States | 10 | 2025 | 14841 | 0.150 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2008 | 22 | 0.140 |
Why?
| | Sex Characteristics | 1 | 2023 | 762 | 0.140 |
Why?
| | Case-Control Studies | 7 | 2012 | 3556 | 0.140 |
Why?
| | Prospective Studies | 9 | 2022 | 7604 | 0.140 |
Why?
| | Inpatients | 1 | 2021 | 500 | 0.140 |
Why?
| | Predictive Value of Tests | 7 | 2009 | 2031 | 0.130 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1291 | 0.120 |
Why?
| | Ovariectomy | 2 | 2008 | 152 | 0.120 |
Why?
| | Placebos | 2 | 2021 | 199 | 0.120 |
Why?
| | Prevalence | 3 | 2025 | 2734 | 0.110 |
Why?
| | Anticholesteremic Agents | 2 | 2009 | 153 | 0.110 |
Why?
| | Comorbidity | 4 | 2025 | 1622 | 0.110 |
Why?
| | Adult | 8 | 2025 | 37929 | 0.100 |
Why?
| | Pragmatic Clinical Trials as Topic | 2 | 2025 | 65 | 0.100 |
Why?
| | Hydroxycholesterols | 1 | 2012 | 5 | 0.100 |
Why?
| | Primary Prevention | 4 | 2007 | 196 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2024 | 2654 | 0.100 |
Why?
| | Colorectal Neoplasms | 4 | 2013 | 806 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2025 | 310 | 0.090 |
Why?
| | Quality of Life | 2 | 2022 | 2892 | 0.090 |
Why?
| | Regression Analysis | 2 | 2004 | 1024 | 0.090 |
Why?
| | Receptors, Estrogen | 2 | 2012 | 436 | 0.090 |
Why?
| | Prognosis | 4 | 2024 | 4030 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 6 | 2010 | 2691 | 0.090 |
Why?
| | Odds Ratio | 3 | 2008 | 1070 | 0.090 |
Why?
| | Cholecalciferol | 1 | 2010 | 60 | 0.080 |
Why?
| | Age Factors | 3 | 2007 | 3295 | 0.080 |
Why?
| | Hyperlipoproteinemia Type II | 1 | 2010 | 35 | 0.080 |
Why?
| | Fractures, Bone | 2 | 2006 | 380 | 0.080 |
Why?
| | Coronary Vessels | 2 | 2008 | 248 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7635 | 0.080 |
Why?
| | Bone Density Conservation Agents | 1 | 2010 | 80 | 0.080 |
Why?
| | Disease Progression | 4 | 2004 | 2757 | 0.080 |
Why?
| | Menopause | 1 | 2012 | 320 | 0.080 |
Why?
| | Survival Analysis | 4 | 2007 | 1325 | 0.080 |
Why?
| | Apolipoprotein A-I | 1 | 2009 | 30 | 0.080 |
Why?
| | Medroxyprogesterone | 1 | 2008 | 11 | 0.080 |
Why?
| | Breast Neoplasms | 3 | 2013 | 2253 | 0.070 |
Why?
| | Epidemiologic Methods | 1 | 2009 | 97 | 0.070 |
Why?
| | Rest | 1 | 2009 | 121 | 0.070 |
Why?
| | von Willebrand Factor | 1 | 2008 | 80 | 0.070 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2008 | 132 | 0.070 |
Why?
| | Homocysteine | 1 | 2008 | 156 | 0.070 |
Why?
| | Factor VIII | 1 | 2008 | 98 | 0.070 |
Why?
| | Leukocyte Count | 1 | 2008 | 329 | 0.070 |
Why?
| | Insulin | 3 | 2008 | 2409 | 0.070 |
Why?
| | Calcium | 3 | 2008 | 1199 | 0.070 |
Why?
| | Chi-Square Distribution | 2 | 2007 | 530 | 0.070 |
Why?
| | France | 1 | 2007 | 33 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2007 | 1509 | 0.070 |
Why?
| | Death | 1 | 2007 | 119 | 0.070 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 99 | 0.070 |
Why?
| | Panic Disorder | 1 | 2006 | 24 | 0.060 |
Why?
| | Cohort Studies | 2 | 2022 | 5742 | 0.060 |
Why?
| | Albuminuria | 1 | 2007 | 185 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2025 | 15657 | 0.060 |
Why?
| | Hip Fractures | 4 | 2013 | 86 | 0.060 |
Why?
| | Registries | 2 | 2025 | 2035 | 0.060 |
Why?
| | Chest Pain | 1 | 2006 | 91 | 0.060 |
Why?
| | Blood Pressure | 3 | 2008 | 1786 | 0.060 |
Why?
| | Down-Regulation | 1 | 2008 | 657 | 0.060 |
Why?
| | Sex Factors | 3 | 2010 | 2071 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2008 | 611 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5472 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 660 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 233 | 0.060 |
Why?
| | Algorithms | 2 | 2003 | 1704 | 0.060 |
Why?
| | Up-Regulation | 1 | 2008 | 843 | 0.060 |
Why?
| | Age Distribution | 1 | 2006 | 392 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2007 | 220 | 0.060 |
Why?
| | Thrombophilia | 1 | 2025 | 83 | 0.060 |
Why?
| | Cost of Illness | 1 | 2007 | 308 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 778 | 0.050 |
Why?
| | Evidence-Based Practice | 1 | 2007 | 229 | 0.050 |
Why?
| | Coronary Stenosis | 1 | 2024 | 38 | 0.050 |
Why?
| | Diabetic Angiopathies | 1 | 2006 | 259 | 0.050 |
Why?
| | Drug Combinations | 4 | 2006 | 343 | 0.050 |
Why?
| | Progesterone Congeners | 1 | 2003 | 16 | 0.050 |
Why?
| | Kidney Diseases | 1 | 2007 | 408 | 0.050 |
Why?
| | Plaque, Atherosclerotic | 1 | 2024 | 57 | 0.050 |
Why?
| | Recurrence | 1 | 2007 | 1060 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 74 | 0.050 |
Why?
| | Bone Density | 2 | 2006 | 489 | 0.050 |
Why?
| | Glucose Intolerance | 1 | 2004 | 146 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2189 | 0.050 |
Why?
| | Treatment Failure | 1 | 2004 | 356 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2005 | 333 | 0.050 |
Why?
| | Cause of Death | 2 | 2021 | 434 | 0.050 |
Why?
| | Tissue Plasminogen Activator | 1 | 2004 | 224 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2007 | 561 | 0.050 |
Why?
| | Leg | 1 | 2004 | 236 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 7 | 0.050 |
Why?
| | Depressive Disorder | 1 | 2005 | 379 | 0.050 |
Why?
| | Mobility Limitation | 1 | 2022 | 61 | 0.050 |
Why?
| | Reference Values | 1 | 2003 | 816 | 0.050 |
Why?
| | Echocardiography | 1 | 2024 | 642 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 2057 | 0.040 |
Why?
| | Frailty | 1 | 2024 | 170 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2025 | 565 | 0.040 |
Why?
| | Intermittent Claudication | 1 | 2022 | 118 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 106 | 0.040 |
Why?
| | Body Mass Index | 1 | 2009 | 2389 | 0.040 |
Why?
| | Primates | 1 | 2021 | 126 | 0.040 |
Why?
| | Extremities | 1 | 2021 | 131 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 394 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 1289 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2024 | 766 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2006 | 940 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 1007 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2023 | 744 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 862 | 0.030 |
Why?
| | Smoking | 1 | 2004 | 1627 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 827 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 2 | 2009 | 889 | 0.030 |
Why?
| | Colorado | 1 | 2025 | 4565 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1381 | 0.030 |
Why?
| | Colonic Polyps | 2 | 2006 | 88 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2021 | 1430 | 0.030 |
Why?
| | Pregnancy | 1 | 2024 | 6763 | 0.020 |
Why?
| | Endometrial Neoplasms | 1 | 2013 | 201 | 0.020 |
Why?
| | Estrogen Receptor beta | 1 | 2010 | 40 | 0.020 |
Why?
| | Early Termination of Clinical Trials | 1 | 2010 | 17 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 145 | 0.020 |
Why?
| | Muscular Diseases | 1 | 2010 | 114 | 0.020 |
Why?
| | Adolescent | 2 | 2023 | 21513 | 0.020 |
Why?
| | Diastole | 1 | 2008 | 149 | 0.020 |
Why?
| | Systole | 1 | 2008 | 189 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 2007 | 80 | 0.020 |
Why?
| | Angina, Unstable | 1 | 2007 | 76 | 0.020 |
Why?
| | Reference Standards | 1 | 2007 | 186 | 0.020 |
Why?
| | Probability | 1 | 2007 | 304 | 0.020 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2007 | 141 | 0.020 |
Why?
| | Diet Records | 1 | 2006 | 83 | 0.020 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2006 | 59 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 499 | 0.020 |
Why?
| | Kidney Calculi | 1 | 2006 | 38 | 0.020 |
Why?
| | Likelihood Functions | 1 | 2006 | 144 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2006 | 73 | 0.010 |
Why?
| | Coronary Artery Bypass | 1 | 2007 | 234 | 0.010 |
Why?
| | Gonadal Steroid Hormones | 1 | 2006 | 140 | 0.010 |
Why?
| | Health Surveys | 1 | 2006 | 514 | 0.010 |
Why?
| | Drug Interactions | 1 | 2006 | 410 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2007 | 1316 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2004 | 88 | 0.010 |
Why?
| | Renin-Angiotensin System | 1 | 2004 | 85 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2007 | 746 | 0.010 |
Why?
| | Forearm Injuries | 1 | 2003 | 7 | 0.010 |
Why?
| | Progestins | 1 | 2004 | 79 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 282 | 0.010 |
Why?
| | Adenoma | 1 | 2006 | 230 | 0.010 |
Why?
| | Fibrinogen | 1 | 2004 | 168 | 0.010 |
Why?
| | Wrist Injuries | 1 | 2003 | 23 | 0.010 |
Why?
| | Electrocardiography | 1 | 2006 | 629 | 0.010 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2003 | 42 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 2006 | 413 | 0.010 |
Why?
| | Syndrome | 1 | 2004 | 358 | 0.010 |
Why?
| | Canada | 1 | 2004 | 418 | 0.010 |
Why?
| | Survival Rate | 1 | 2007 | 1972 | 0.010 |
Why?
| | Energy Intake | 1 | 2006 | 485 | 0.010 |
Why?
| | Fatty Acids | 1 | 2006 | 443 | 0.010 |
Why?
| | Antigens | 1 | 2004 | 357 | 0.010 |
Why?
| | Cardiovascular System | 1 | 2004 | 137 | 0.010 |
Why?
| | Logistic Models | 1 | 2007 | 2074 | 0.010 |
Why?
| | Patient Compliance | 1 | 2006 | 581 | 0.010 |
Why?
| | Body Weight | 1 | 2006 | 985 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1793 | 0.010 |
Why?
| | Heart Diseases | 1 | 2003 | 346 | 0.010 |
Why?
| | Lipids | 1 | 2004 | 672 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2007 | 2828 | 0.010 |
Why?
| | Animals | 1 | 2021 | 36940 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6828 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 1139 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2004 | 1208 | 0.010 |
Why?
| | Obesity | 1 | 2004 | 2992 | 0.010 |
Why?
| | Child | 1 | 2010 | 21935 | 0.010 |
Why?
|
|
Hsia's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|